+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

R

Actively Recruiting

This research aims to evaluate the clinical effectiveness, safety, and tolerability of XEN1101 when used alongside other antiseizure medications in adults with focal-onset seizures. It is a Phase 3, randomized, double-blind, placebo-controlled study involving approximately 360 participants. The study focuses on how XEN1101 affects seizure frequency compared to placebo while monitoring any side effects or safety concerns. Participants will be randomly assigned to one of three groups XEN1101 25 mg, XEN1101 15 mg, or placebo, taken once daily with an evening meal. The study includes a baseline period of up to 9.5 weeks to record seizure frequency, followed by 12 weeks of blinded treatment. After this, those who complete the treatment phase may join an open-label extension study for continued XEN1101 treatment, while others will enter an 8-week post-treatment follow-up period. During the study, participants will keep accurate seizure diaries and attend regular visits for assessments including seizure monitoring, safety checks, and tolerability evaluations. Researchers will measure the median percent change in focal seizure frequency from baseline through the 12-week treatment, along with other outcomes such as the proportion of participants experiencing significant seizure reduction and patient-reported global impressions. Safety is monitored from screening through 56 days after the final dose to ensure participant well-being throughout the trial.

Age: 18Years +All GendersPhase 3
103 locations
A

Actively Recruiting

Researchers are evaluating the effectiveness and safety of Staccato alprazolam, an inhaled medication, in people aged 12 years and older who experience stereotypical prolonged seizures. The study aims to compare a single dose of Staccato alprazolam with a placebo in quickly stopping a seizure within 90 seconds and preventing further seizures for up to 2 hours after treatment. Participants are randomly assigned to receive either one dose of Staccato alprazolam or a matching placebo by inhalation in this double-blind study. This single-dose treatment is given during the outpatient treatment period, and participants are monitored closely to assess seizure control and safety. During the study, participants will have their seizures evaluated for treatment success within 90 seconds and for any recurrence up to 6 hours after dosing. Researchers will also monitor respiratory events and seizure frequency. Participants will have regular assessments, including safety follow-up visits extending up to 19 weeks after treatment, to ensure thorough monitoring of effects and any adverse events.

Age: 12Years +All GendersPhase 3
183 locations
O

Actively Recruiting

Crohns disease is a chronic inflammatory condition affecting the digestive tract and is currently incurable. This research aims to evaluate how safe and effective the drug upadacitinib is for treating moderately to severely active Crohns disease in real-world settings. The study will monitor any adverse events and track changes in disease activity among participants. All participants will receive upadacitinib as prescribed by their own doctors according to approved local guidelines. The study plans to enroll about 240 participants in Japan who have recently started upadacitinib treatment. Treatment will follow routine clinical practice without altering the prescribed approach. Participants will be followed for up to 64 weeks with visits that may occur in person or virtually, aligned with standard care. Researchers will assess outcomes such as the percentage of participants experiencing serious infections related to the drug. There is expected to be no extra burden beyond usual medical care throughout the study period.

Age: 15Years +All Genders
104 locations